Author's response to reviews

Title: Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer

Authors:

Ryuichiro Koshimune (koshiryu16@hotmail.com)
Motoi Aoe (motoiae@md.okayama-u.ac.jp)
Shinichi Toooka (s_toyooka@nigeka2.hospital.okayama-u.ac.jp)
Fumikata Hara (fumi7hara@hotmail.com)
Mamoru Ouchida (ouchidam@md.okayama-u.ac.jp)
Masaki Tokumo (masakitoku@yahoo.co.jp)
Yoshifumi Sano (ysano@md.okayama-u.ac.jp)
Hiroshi Date (hdate@md.okayama-u.ac.jp)
Nobuyoshi Shimizu (dr_lung@md.okayama-u.ac.jp)

Version: 8 Date: 7 January 2007

Author's response to reviews: see over
January 7, 2007

Dear Editor:

Thank you for your recent notification regarding the above mentioned manuscript, provisionally accepting the manuscript for publication pending minor revision. As detailed on the following page, we have responded to the Reviewers’ helpful comments. We hope that our revised manuscript will be accepted in BMC Cancer as an original report.

Best wishes,

Ryuichiro Koshimune, M.D.

Reviewer's report:

Minor points
The Rap1A antibody the authors used recognized only unprenylated Rap1A although Santa Cruz Biotechnologies named it only Rap1A antibody. Then this antibody is useful for monitoring the prenylation status. In order to let the readers better understand, please describe “goat polyclonal anti-unprenylated Rap1A antibody” in page 8 line 15 and “anti-unprenylated Rap1A antibody” in page 11, line 4. Although authors demonstrated the YM529 inhibited the farnesylation and the geranylgeranylation of the small G-protein and pERK1/2 in NSCLC cells, authors did not demonstrate any Ras-contribution for perk pathway. The molecular target of YM529 remains unknown. Therefore, I recommend that the authors should revise the following sentence.

Page 11, line 6
These results suggested that YM529 inhibited ERK1/2 pathway (not Ras-ERK1/2) via inhibition of farnesylation and/or geranylgeranylation of GTP-binding proteins.

We really appreciate educational suggestions. We accept these suggestions and revise sentence (in page 8 line 15)( page 11, line 4)(Page 11, line 6).